Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

Oncotarget

Volumn 7, Issue 34, 2016, Pages 54564-54571

  Lolli, Cristian ^a   Basso, Umberto ^b   Derosa, Lisa ^c   Scarpi, Emanuela ^a   Sava, Teodoro ^d   Santoni, Matteo ^e   Crabb, Simon J ^f   Massari, Francesco ^d,h   Aieta, Michele ^g   Conteduca, Vincenza ^a   Maruzzo, Marco ^b   La Russa, Francesca ^d   Wheater, Matthew ^f   Berardi, Rossana ^e   Galli, Luca ^c   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^g REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Prognostic factor; RCC; Renal cell carcinoma; Sunitinib; Systemic immune inflammation index

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; KIDNEY METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SYSTEMIC IMMUNE INFLAMMATION INDEX; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; IMMUNOLOGY; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RENAL CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PYRROLES; RETROSPECTIVE STUDIES;

EID: 84983542759     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10515     Document Type: Article

References (28)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger B. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Oncotarget 2015; 6:11395-406. doi: 10.18632/oncotarget.3456.
3. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004; 10:6290S-5S.
4. Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, Iacovelli R, Burattini L, Santini D, Montironi R, Cascinu S, Principato G. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget 2015; 6:32161-8. doi: 10.18632/oncotarget.5147.
5. Dabney R, Devine R, Sein N, George B. New agents in renal cell carcinoma. Target Oncol. 2014; 9:183-93.
6. Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, et al. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. Clin Genitourin Cancer. 2015; 13:150-5.
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-44.
8. Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, Bianchi E, Savini A, Burgio SL, Conti A, Conteduca V, Cascinu S, De Giorgi U. High neutrophil-tolymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015; 22:1377-84.
9. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009; 16:614-22
10. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ. High blood neutrophil-tolymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010; 16:5805-13.
11. Conteduca V, Crabb SJ, Scarpi E, Hanna C, Maines F, Joyce H, Fabbri P, Derosa L, Massari F, Lolli C, Zarif S, Jones RJ, Caffo O, et al. High neutrophil to lymphocyte ratio persistent during enzalutamide and clinical outcome in patients with castration resistant prostate cancer. Plos One in press
12. Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, Luca Burgio S, Berardi R, Muzzonigro G, Cortesi E, Amadori D, Cascinu S. Pre-treatment neutrophilto-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013; 109:1755-9.
13. Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a metaanalysis. BMJ Open. 2015 Apr 8; 5:e006404.
14. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immuneinflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20:6212-22.
15. Schumacher D, Strilic B, Sivaraj KK, et al. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013; 24:130-137.
16. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces epithelial-mesenchymallike transition and promote metastasis. Cancer Cell 2011; 20:576-590.
17. Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophyl extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 2013; 123:3446-58.
18. López-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene. 2013; 32:1752-60.
19. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012; 12:264-9.
20. Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Identification of programmed death ligand 1-derived peptides capable of inducing cancerreactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. J Immunother. 2015; 38:285-91.
21. Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, et al. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol. 2016 Feb 25 (advance online publication)
22. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophilto-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106: dju124.
23. Saroha S, Uzzo RG, Plimack ER, Ruth K, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013; 189:454-61.
24. De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, et al. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. J Geriatr Oncol. 2014; 5:156-63.
25. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27:5794-9.
26. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14:141-8.
27. Passardi A, Scarpi E, Tamberi S, Cavanna L, Tassinari D, Fontana A, Bernardini I, Accettura C, Tenti E, Vespignani R, Frassineti GL, Amadori D, De Giorgi U. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget. 2016 Apr 21. doi: 10.18632/oncotarget.8901.
28. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803-13.